What is Uman Pharma?
Headquartered in Candiac, Quebec, Uman Pharma operates as a specialized manufacturer of cytotoxic and high-potent sterile injectables. The company serves the oncology market by providing both complex and generic formulations, supported by a robust 11,700-square-meter GMP-certified facility. By focusing on the high-barrier-to-entry segment of sterile injectables, Uman Pharma has established a competitive moat, leveraging its technical expertise to meet the rigorous demands of global healthcare providers and oncology specialists.
The company's operational model integrates advanced manufacturing processes with a highly skilled workforce, ensuring compliance with international quality standards. This infrastructure allows Uman Pharma to maintain a consistent supply chain for critical cancer treatments, positioning the firm as a vital partner in the pharmaceutical ecosystem. Its commitment to high-potency drug development reflects a strategic alignment with the increasing global demand for specialized oncology therapies.
How much funding has Uman Pharma raised?
Uman Pharma has raised a total of $27M across 1 funding round:
Other Financing Round
$27M
Other Financing Round (2011): $27M with participation from CFR Pharmaceuticals
Key Investors in Uman Pharma
CFR Pharmaceuticals
CFR Pharmaceuticals is a prominent Latin American pharmaceutical entity, formerly independent and now integrated into Abbott Laboratories, with a vast distribution network spanning multiple continents.
What's next for Uman Pharma?
Looking ahead, the recent capital allocation is expected to accelerate Uman Pharma's expansion into new therapeutic markets and enhance its existing production capacity. As the firm navigates the complexities of the oncology sector, the focus will likely remain on optimizing its sterile injectable portfolio and exploring further international distribution channels. By leveraging its established manufacturing footprint, Uman Pharma is well-positioned to capitalize on the growing need for high-potency drug manufacturing, potentially attracting further strategic partnerships or investment as it scales its global footprint.
See full Uman Pharma company page
